In addition to the protective effect of TRPM8 in prostate cancer, it was demonstrated the advantage of using nanocarriers on the improved activity of the channel agonist, as encapsulation decreased the concentration required to activate the channel. Here, TRPM8 is linked to Familial prostate cancer.